Another hypothesis on the enhancement of GDF15 levels could be linked to the disruption of the intestinal barrier and lipopolysaccharide (LPS) translocation and consequent systemic inflammation in MASLD [22], in line with experimental evidence of LPS-dependent elevation in plasmatic GDF15 levels [23]. The gene discussed is GDF15; the disease is metabolic dysfunction-associated steatotic liver disease.